Exelon Co. (NYSE:EXC) has received a consensus rating of “Buy” from the seventeen research firms that are presently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $50.10.
A number of research analysts recently issued reports on the company. Wells Fargo & Co set a $68.00 target price on Emergent Biosolutions and gave the company a “hold” rating in a report on Tuesday, April 2nd. Barclays reaffirmed a “top pick” rating and set a GBX 3,250 ($42.47) price target on shares of in a report on Wednesday, June 19th. KeyCorp initiated coverage on Southern in a report on Tuesday, June 4th. They set a “sector weight” rating for the company. Goldman Sachs Group raised Exelon from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $48.00 to $52.00 in a report on Thursday, June 6th. Finally, Mizuho decreased their price target on Depomed from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Thursday, May 16th.
NYSE:EXC traded down $1.19 during midday trading on Tuesday, reaching $47.57. The company had a trading volume of 6,827,044 shares, compared to its average volume of 5,214,276. The firm has a market cap of $46.19 billion, a price-to-earnings ratio of 15.25, a price-to-earnings-growth ratio of 4.24 and a beta of 0.37. The business’s fifty day simple moving average is $49.20. Exelon has a 12-month low of $40.97 and a 12-month high of $51.18. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.02 and a quick ratio of 0.89.
In related news, CEO Calvin Butler, Jr. sold 31,000 shares of the business’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $47.59, for a total value of $1,475,290.00. Following the transaction, the chief executive officer now owns 40,331 shares in the company, valued at approximately $1,919,352.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kenneth W. Cornew sold 54,300 shares of the business’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $49.82, for a total value of $2,705,226.00. Following the completion of the transaction, the executive vice president now owns 97,813 shares in the company, valued at approximately $4,873,043.66. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Bank & Trust acquired a new stake in shares of Exelon in the 1st quarter worth approximately $25,000. Centersquare Investment Management LLC acquired a new stake in shares of Exelon in the 1st quarter worth approximately $26,000. Capital Financial Planning LLC acquired a new stake in shares of Exelon in the 4th quarter worth approximately $29,000. LFA Lugano Financial Advisors SA acquired a new stake in shares of Exelon in the 1st quarter worth approximately $29,000. Finally, Weaver Consulting Group acquired a new stake in shares of Exelon in the 1st quarter worth approximately $31,000. Institutional investors own 79.77% of the company’s stock.
Exelon Corporation, a utility services holding company, engages in energy generation and delivery businesses in the United States and Canada. It owns nuclear, fossil, wind, hydroelectric, and solar generating facilities. The company also sells electricity to wholesale and retail customers; and sells natural gas, renewable energy, and other energy-related products and services.
Featured Story: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Exelon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelon and related companies with MarketBeat.com's FREE daily email newsletter.